A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Related Articles

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Blood. 2017 01 19;129(3):383-385

Authors: Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M, AGMT Investigators

PMID: 27879257 [PubMed - indexed for MEDLINE]

http://ift.tt/2fuxmGd